Crossmark

A multi-faceted discovery strategy identifies functional antibodies binding to cysteine-rich domain 1 of hDKK1 for cancer immunotherapy via Wnt non-canonical pathway

Crossref DOI link: https://doi.org/10.1038/s41388-025-03445-6

Published Online: 2025-05-20

Published Print: 2025-08-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Linya https://orcid.org/0009-0008-6816-215X
Peterson, Sean M.

Yang, Marisa https://orcid.org/0000-0002-9898-2094
Lujan Hernandez, Ana G.

Yuan, Tom Z.

Han, Zhen

Prabhu, Vishwas

Chan, Kara Y.

Hu, Cameron F.

Villalta, Mouna

Htoy, Tammy

VanDyke, Paul

Holliday, Carson

Franco, Hector

Wadhwa, Hansika

Giang, Hoa

Stafford, Ryan

Axelrod, Fumiko

Sato, Aaron
License Information

Text and Data Mining valid from 2025-05-20

Version of Record valid from 2025-05-20
More Information

Article History

Received: 13 December 2024

Revised: 1 April 2025

Accepted: 12 May 2025

First Online: 20 May 2025

Competing interests

: The authors declare no competing interests.

: All methods were performed in accordance with the relevant guidelines and regulations. Approval has been obtained from Biocytogen Boston (Boston, MA, USA) Institutional Animal Care and Use Committee (IACUC AUP# 2018N001). There is no human research participant in this study.

Document is current

Any future updates will be listed below